OPNT
NASDAQOpiant Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Latest news
25 items- FDAFDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INCSubmission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form
- FDAMay 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid OverdoseFor Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA
- FDAFDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INCSubmission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form
- SECSEC Form 15-12G filed by Opiant Pharmaceuticals Inc.15-12G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
- SECSEC Form EFFECT filed by Opiant Pharmaceuticals Inc.EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
- SECSEC Form EFFECT filed by Opiant Pharmaceuticals Inc.EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
- SECSEC Form EFFECT filed by Opiant Pharmaceuticals Inc.EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
- INSIDERSEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Collard Craig A returned $1,116,440 worth of shares to the company (55,822 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Ruth Matthew R. returned $638,320 worth of shares to the company (31,916 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Daly Richard J returned $156,000 worth of shares to the company (7,800 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Crystal Roger was granted 6,667 shares, returned $1,640,120 worth of shares to the company (82,006 units at $20.00) and returned $102,000 worth of Common Stock par value $0.001 to the company (5,100 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Ellison Mark Jason Heath returned $608,620 worth of shares to the company (30,431 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Skolnick Phil returned $470,960 worth of shares to the company (23,548 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Sinclair Michael returned $1,803,400 worth of shares to the company (90,170 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Macdougall Ann L. returned $563,580 worth of shares to the company (28,179 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Lorianne Masuoka K. returned $80,000 worth of shares to the company (4,000 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Gorman Brian was granted 2,000 shares and returned $679,800 worth of shares to the company (33,990 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: Thomas Thomas T. returned $247,500 worth of shares to the company (12,375 units at $20.00), closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- INSIDERSEC Form 4: O'Toole David D returned $724,960 worth of shares to the company (36,248 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
- NEWSIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioIndivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) The transaction strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl. Financial Consideration On November 13, 2022, Indivior and Opiant entered into a definitive agreement under which Indivior would acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up
- SECSEC Form 25-NSE filed by Opiant Pharmaceuticals Inc.25-NSE - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)
- SECOpiant Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits8-K - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
- SECOpiant Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
- SECOpiant Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
OPNT FAQ
6 questionsWhat does Opiant Pharmaceuticals Inc. do?
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa...Where does OPNT stock trade?
Opiant Pharmaceuticals Inc. (OPNT) is listed on NASDAQ.What sector and industry is OPNT in?
Opiant Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about OPNT?
Opiant Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Oppenheimer: Outperform with a $4200.00 price target on 2021-12-09. Recent price targets cluster around $4200.00.What companies are similar to OPNT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OPNT side-by-side with any of them on Quantisnow.How can I track OPNT on Quantisnow?
Quantisnow aggregates Opiant Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OPNT to receive live email and push alerts on every new disclosure.